Selected research
Industry Research
Insulin Biologics and Biosimilars Industry Research Report 2026
Market perspective
The global Insulin Biologics and Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Insulin Biologics and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Insulin Biologics and Biosimilars market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Insulin Biologics and Biosimilars market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Insulin Biologics and Biosimilars include Tonghua Dongbao, Sanofi, Novo Nordisk, Eli Lilly, Wockhardt, United Laboratory, Geropharm, Gan&Lee and Biocon. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Insulin Biologics and Biosimilars market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Insulin Biologics and Biosimilars.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Insulin Biologics and Biosimilars Market by Company
Tonghua Dongbao
Sanofi
Novo Nordisk
Eli Lilly
Wockhardt
United Laboratory
Geropharm
Gan&Lee
Biocon
Insulin Biologics and Biosimilars Segment by Type
Insulin Biologics
Insulin Biosimilars
Insulin Biologics and Biosimilars Segment by Application
Hospital
Retail Pharmacy
Other
Insulin Biologics and Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Insulin Biologics and Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin Biologics
- Insulin Biosimilars
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Tonghua Dongbao
- Sanofi
- Novo Nordisk
- Eli Lilly
- Wockhardt
- United Laboratory
- Geropharm
- Gan&Lee
- Biocon
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Insulin Biologics and Biosimilars by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Insulin Biologics
- 2.2.3 Insulin Biosimilars
- 2.3 Insulin Biologics and Biosimilars by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Insulin Biologics and Biosimilars Breakdown Data by Type
- 3.1 Global Insulin Biologics and Biosimilars Historic Market Size by Type (2021-2026)
- 3.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Type (2027-2032)
4 Insulin Biologics and Biosimilars Breakdown Data by Application
- 4.1 Global Insulin Biologics and Biosimilars Historic Market Size by Application (2021-2026)
- 4.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Insulin Biologics and Biosimilars Market Perspective (2021-2032)
- 5.2 Global Insulin Biologics and Biosimilars Growth Trends by Region
- 5.2.1 Global Insulin Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Insulin Biologics and Biosimilars Historic Market Size by Region (2021-2026)
- 5.2.3 Insulin Biologics and Biosimilars Forecasted Market Size by Region (2027-2032)
- 5.3 Insulin Biologics and Biosimilars Market Dynamics
- 5.3.1 Insulin Biologics and Biosimilars Industry Trends
- 5.3.2 Insulin Biologics and Biosimilars Market Drivers
- 5.3.3 Insulin Biologics and Biosimilars Market Challenges
- 5.3.4 Insulin Biologics and Biosimilars Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Insulin Biologics and Biosimilars Players by Revenue
- 6.1.1 Global Top Insulin Biologics and Biosimilars Players by Revenue (2021-2026)
- 6.1.2 Global Insulin Biologics and Biosimilars Revenue Market Share by Players (2021-2026)
- 6.2 Global Insulin Biologics and Biosimilars Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Insulin Biologics and Biosimilars Head Office and Area Served
- 6.4 Global Insulin Biologics and Biosimilars Players, Product Type & Application
- 6.5 Global Insulin Biologics and Biosimilars Manufacturers Established Date
- 6.6 Global Insulin Biologics and Biosimilars Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Insulin Biologics and Biosimilars Market Size (2021-2032)
- 7.2 North America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 7.4 North America Insulin Biologics and Biosimilars Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Insulin Biologics and Biosimilars Market Size (2021-2032)
- 8.2 Europe Insulin Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 8.4 Europe Insulin Biologics and Biosimilars Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Insulin Biologics and Biosimilars Market Size (2021-2032)
- 9.2 Asia-Pacific Insulin Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Insulin Biologics and Biosimilars Market Size (2021-2032)
- 10.2 South America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 10.4 South America Insulin Biologics and Biosimilars Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Insulin Biologics and Biosimilars Market Size (2021-2032)
- 11.2 Middle East & Africa Insulin Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Tonghua Dongbao
- 12.1.1 Tonghua Dongbao Company Information
- 12.1.2 Tonghua Dongbao Business Overview
- 12.1.3 Tonghua Dongbao Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.1.4 Tonghua Dongbao Insulin Biologics and Biosimilars Product Portfolio
- 12.1.5 Tonghua Dongbao Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.2.4 Sanofi Insulin Biologics and Biosimilars Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Novo Nordisk
- 12.3.1 Novo Nordisk Company Information
- 12.3.2 Novo Nordisk Business Overview
- 12.3.3 Novo Nordisk Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.3.4 Novo Nordisk Insulin Biologics and Biosimilars Product Portfolio
- 12.3.5 Novo Nordisk Recent Developments
- 12.4 Eli Lilly
- 12.4.1 Eli Lilly Company Information
- 12.4.2 Eli Lilly Business Overview
- 12.4.3 Eli Lilly Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.4.4 Eli Lilly Insulin Biologics and Biosimilars Product Portfolio
- 12.4.5 Eli Lilly Recent Developments
- 12.5 Wockhardt
- 12.5.1 Wockhardt Company Information
- 12.5.2 Wockhardt Business Overview
- 12.5.3 Wockhardt Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.5.4 Wockhardt Insulin Biologics and Biosimilars Product Portfolio
- 12.5.5 Wockhardt Recent Developments
- 12.6 United Laboratory
- 12.6.1 United Laboratory Company Information
- 12.6.2 United Laboratory Business Overview
- 12.6.3 United Laboratory Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.6.4 United Laboratory Insulin Biologics and Biosimilars Product Portfolio
- 12.6.5 United Laboratory Recent Developments
- 12.7 Geropharm
- 12.7.1 Geropharm Company Information
- 12.7.2 Geropharm Business Overview
- 12.7.3 Geropharm Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.7.4 Geropharm Insulin Biologics and Biosimilars Product Portfolio
- 12.7.5 Geropharm Recent Developments
- 12.8 Gan&Lee
- 12.8.1 Gan&Lee Company Information
- 12.8.2 Gan&Lee Business Overview
- 12.8.3 Gan&Lee Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.8.4 Gan&Lee Insulin Biologics and Biosimilars Product Portfolio
- 12.8.5 Gan&Lee Recent Developments
- 12.9 Biocon
- 12.9.1 Biocon Company Information
- 12.9.2 Biocon Business Overview
- 12.9.3 Biocon Revenue in Insulin Biologics and Biosimilars Business (2021-2026)
- 12.9.4 Biocon Insulin Biologics and Biosimilars Product Portfolio
- 12.9.5 Biocon Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst